Geographic Atrophy Market Analysis: $2.4 Billion Market Size In 2026 And Future Growth Prospects

Geographic Atrophy Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Geographic Atrophy Market Forecast: Value Set To Climb From $2.4 Billion To $3.92 Billion

The market for geographic atrophy has experienced rapid growth in recent years. It is projected to expand from $2.11 billion in 2025 to $2.4 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.3%. Historically, this expansion has been attributed to factors including an increasing aging population, the prevalence of age-related macular degeneration, advancements in retinal imaging, early ophthalmic drug development, and funding for clinical research.

The geographic atrophy market is anticipated to experience significant expansion over the coming years. This market is projected to reach $3.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. This expansion during the forecast period is propelled by factors such as the introduction of new therapies, broader screening initiatives, the incorporation of AI-powered imaging, heightened patient awareness, and the advancement of specialized eye care services. Key trends anticipated during this period encompass the increasing development of complement inhibitor treatments, a stronger emphasis on the early detection of retinal conditions, greater investment in innovative ophthalmic medications, the widespread use of imaging technologies for disease surveillance, and an increase in clinical trials for AMD treatments.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=71754057&type=smp&name=Geographic%20Atrophy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Geographic Atrophy Market Growth Factors: What’s Supporting Expansion?

The geographic atrophy market is anticipated to expand due to the escalating incidence of age-related macular degeneration. Age-related macular degeneration (AMD) is an ocular ailment that impairs the central retina in older adults, hindering their perception of fine details. The aging demographic is a primary contributor to the widespread occurrence of AMD, as extended lifespans lead to gradual ocular damage through natural aging, making eyes more susceptible to the condition over time. Geographic atrophy treatments offer assistance to age-related macular degeneration (AMD) patients by retarding the advancement of retinal damage and preserving residual vision. For instance, in January 2024, a report released by Medical News Today, a US-based digital media company, projected that global instances of age-related macular degeneration would increase from 196 million to 288 million by 2040. Thus, the rising prevalence of age-related macular degeneration is a significant impetus for the growth of the geographic atrophy market.

Geographic Atrophy Market Segmentation: How Does The Market Break Down By Category?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

Geographic Atrophy Market Trends Shaping Long-Term Demand

Leading companies active in the geographic atrophy market are concentrating on pioneering therapies like complement inhibitor therapy to create enhanced treatments for geographic atrophy. Complement inhibitor therapy is a method that decelerates an overly active immune response connected to specific diseases, helping to shield healthy cells from harm and diminish the progression of the disease. For instance, in February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company, announced that IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy received approval from the Food and Drug Administration, a US-based government agency. This approval permits IZERVAY to be utilized without any restrictions on the dosing duration for addressing geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This ruling offers increased adaptability for GA management, presenting longer-duration treatment alternatives for both patients and healthcare providers.

Geographic Atrophy Market Competitive Overview And Top Companies

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

View The Full Geographic Atrophy Market Report:

https://thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Geographic Atrophy Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the geographic atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model